Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury

Experimental Eye Research

Volumn 96, Issue 1, 2012, Pages 116-123

  Liu, Ye ^a,b   Hirooka, Kazuyuki ^a   Nishiyama, Akira ^a   Lei, Bai ^a   Nakamura, Takehiro ^a   Itano, Toshifumi ^a   Fujita, Tomoyoshi ^a   Zhang, Jinsong ^b   Shiraga, Fumio ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Aldosterone; Angiotensin II type 1 receptor; Mineralocorticoid receptor antagonist; Retinal ischemia

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; CANDESARTAN; CARBOXYMETHYLCELLULOSE; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LABELING; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; HORMONAL REGULATION; INTRAOCULAR PRESSURE; ISCHEMIA; MALE; NEUROPROTECTION; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; RETINA GANGLION CELL; RETINA INJURY; RETINA THICKNESS; THICKNESS;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; CELL SURVIVAL; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; REPERFUSION INJURY; RETINAL DISEASES; SPIRONOLACTONE; TETRAZOLES;

EID: 84857801152     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2011.12.012     Document Type: Article

References (32)

1. Danser A.H., Derkx F.H., Admiraal P.J., Deinum J., de Jong P.T., Schalekamp M.A. Angiotensin levels in the eye. Investigative Ophthalmology and Visual Science 1994, 35:1008-1018.
2. De Mello W.C., Danser A.H. Angiotensin II and the heart: on the intracrine renin-angiotensin system. Hypertension 2000, 35:1183-1188.
3. Downie L.E., Vessey K., Miller A., Ward M.M., Pianta M.J., Vingrys A.J., Wilkinson-Berka J.L., Fletcher E.L. Neuronal and glial cell expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in the rat retina. Neuroscience 2009, 161:195-213.
4. Fletcher E.L., Phipps J.A., Ward M.M., Vessey K.A., Wilkinson-Berka J.L. The renin-angiotensin system in retinal health and disease: its influence on neurons, glia and the vasculature. Progress in Retinal and Eye Research 2010, 29:284-311.
5. Fukuda K., Hirooka K., Mizote M., Nakamura T., Itano T., Shiraga F. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor. Investigative Ophthalmology and Visual Science 2010, 51:3629-3638.
6. Funck R.C., Wilke A., Rupp H., Brilla C.G. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Advances in Experimental Medicine and Biology 1997, 432:35-44.
7. Greene E.L., Kren S., Hostetter T.H. Role of aldosterone in the remnant kidney model in the rat. The Journal of Clinical Investigation 1996, 98:1063-1068.
8. Harada E., Yoshimura M., Yasue H., Nakagawa O., Nakagawa M., Harada M., Mizuno Y., Nakayama M., Shimasaki Y., Ito T., Nakamura S., Kuwahara K., Saito Y., Nakao K., Ogawa H. Aldosterone induces angiotensin- converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001, 104:137-139.
9. Jurklies B., Eckstein A., Jacobi P., Kohler K., Risler T., Zrenner E. The renin-angiotensin system-a possible neuromodulator in the human retina?. German Journal of Ophthalmology 1995, 4:144-150.
10. Jurklies B., Kohler K., Eikermann J., Zrenner E. Angiotensin II-like immunoreactivity in the retina of some mammalian species. German Journal of Ophthalmology 1994, 3:37-42.
11. Kohler K., Wheeler-Schilling T., Jurklies B., Guenther E., Zrenner E. Angiotensin II in the rabbit retina. Visual Neuroscience 1997, 14:63-71.
12. MacLeod A.B., Vasdev S., Smeda J.S. The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril-treated hypertensive rats. Stroke 1997, 28:1821-1829.
13. Milenkovic V.M., Brockmann M., Meyer C., Desch M., Schweda F., Kurtz A., Todorov V., Sttrauss O. Regulation of the renin expression in the retinal pigment epithelium by systemic stimuli. American Journal of Physiology, Renal Physiology 2010, 299:F396-F403.
14. Murata M., Nakagawa M., Takahashi S. Expression and localization of angiotensin II type 1 receptor mRNA in rat ocular tissues. Ophthalmologica 1997, 211:384-386.
15. Otani A., Takagi H., Suzuma K., Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circulation Research 1998, 82:619-628.
16. Pepperell J.R., Yamada Y., Nemeth G., Palumbo A., Naftolin F. The ovarian renin-angiotensin system. A paracrine-intracrine regulator of ovarian function. Advances in Experimental Medicine and Biology 1995, 377:379-389.
17. Robert V., Heymes C., Silvestre J.S., Sabri A., Swynghedauw B., Delcayre C. Angiotensi AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999, 33:981-986.
18. Rocha R., Chander P.N., Khanna K., Zuckerman A., Stier C.T. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451-458.
19. Rocha R., Chander P.N., Zuckerman A., Stier C.T. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33:232-237.
20. Rogacz S., Williams G.H., Hollenberg N.K. Time course of enhanced adrenal responsiveness to angiotensin on a low salt diet. Hypertension 1990, 15:376-380.
21. Rong P., Wilkinson-Berka J.L., Skinner S.L. Renin in thymus, gut, hindlimb, and adrenal of (mRen-2)27 and normal rats: secretion and content studies. American Journal of Physiology 1999, 277:E639-E646.
22. Rong P., Wilkinson-Berka J.L., Skinner S.L. Control of renin secretion from adrenal gland in transgenic Ren-2 and normal rats. Molecular and Cellular Endocrinology 2001, 173:203-212.
23. Sato A., Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. The Journal of International Medical Research 2001, 29:13-21.
24. Senanayake P., Drazba J., Shadrach K., Milsted A., Rungger-Brandle E., Nishiyama K., Miura S., Karnik S., Sears J.E., Hollyfield J.G. Investigative Ophthalmology and Visual Science 2007, 48:3301-3311.
25. Stier C.T., Benter I.F., Ahmad S., Zuo H.L., Selig N., Roethel S., Levine S., Itskovitz H.D. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension 1989, 13:115-121.
26. Stier C.T., Chander P., Gutstein W.H., Levine S., Itskovitz H.D. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. American Journal of Hypertension 1991, 4:680-687.
27. Wagner J., Jan Danser A.H., Derkx F.H., de Jong T.V., Paul M., Mullins J.J., Schalekamp M.A., Ganten D. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. British Journal of Ophthalmology 1996, 80:159-163.
28. Weber K.T., Brilla C.G., Campbell S.E., Guarda E., Zhou G., Sriram K. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Research in Cardiology 1993, 88:107-124.
29. Wilkinson-Berka J.L., Tan G., Jaworski K., Miller A.G. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circulation Research 2009, 104:124-133.
30. Williams G.H., Burgess E., Kolloch R.E., Ruilope L.M., Nieqowska J., Kipnes M.S., Roniker B., Patrick J.L., Krause S.L. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. American Journal of Cardiology 2004, 93:990-996.
31. Yang H., Hirooka K., Fukuda K., Shiraga F. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of choronic glaucoma. Investigative Ophthalmology and Visual Science 2009, 50:5800-5804.
32. Young M., Head G., Funder J.W. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. American Journal of Physiology 1995, 269:E657-E662.